TY - JOUR
T1 - Treatment of recent-onset type 1 diabetic patients with DiaPep277
T2 - Results of a double-blind, placebo-controlled, randomized phase 3 trial
AU - Raz, Itamar
AU - Ziegler, Anette G.
AU - Linn, Thomas
AU - Schernthaner, Guntram
AU - Bonnici, Francois
AU - Distiller, Larry A.
AU - Giordano, Carla
AU - Giorgino, Francesco
AU - De Vries, Liat
AU - Mauricio, Didac
AU - Procházka, Vlastimil
AU - Wainstein, Julio
AU - Elias, Dana
AU - Avron, Ann
AU - Tamir, Merana
AU - Eren, Rachel
AU - Peled, Dana
AU - Dagan, Shlomo
AU - Cohen, Irun R.
AU - Pozzilli, Paolo
PY - 2014/5
Y1 - 2014/5
N2 - OBJECTIVE: To evaluate safety and efficacy of DiaPep277 in preserving β-cell function in type 1 diabetic patients. RESEARCH DESIGN AND METHODS: DIA-AID 1 is a multinational, phase 3, balanced-randomized, double-blind, placebo-controlled, parallel-group clinical study. Newly diagnosed patients (N = 457, aged 16-45 years) were randomized to subcutaneous injections of DiaPep277 or placebo quarterly for 2 years. The primary efficacy end point was the change from baseline in the area under the glucagon-stimulated C-peptide curve. Secondary end points were the change from baseline in mixed-meal stimulated C-peptide secretion and in fasting C-peptide and achieving target HbA 1c ≤7% (≤53 mmol/mol). Partial remission (target HbA 1c on insulin ≤0.5 units/kg/day) and hypoglycemic event rate were exploratory end points. RESULTS: DiaPep277 was safe and well tolerated. Significant preservation of C-peptide secretion was observed in the DiaPep277-treated group compared with the placebo (relative treatment effects of 23.4%, P = 0.037, and 29.2%, P = 0.011, in the modified intent-to-treat [mITT] and per-protocol [PP] populations, respectively). The mixed-meal stimulation failed to distinguish between the groups. There was a trend toward efficacy in fasting C-peptide levels, though not statistically significant. Significantly more DiaPep277-treated than placebo-treated patients maintained target HbA 1c (mITT 56% versus 44%, P = 0.03; PP 60% versus 45%, P = 0.0082) and entered partial remission (mITT 38% versus 29%, P = 0.08; PP 42% versus 30%, P = 0.035). DiaPep277 treatment reduced the relative hypoglycemic event risk (mITT by 20%; PP by 28%). CONCLUSIONS: DiaPep277 safely contributes to preservation of β-cell function and to improved glycemic control in patients with type 1 diabetes.
AB - OBJECTIVE: To evaluate safety and efficacy of DiaPep277 in preserving β-cell function in type 1 diabetic patients. RESEARCH DESIGN AND METHODS: DIA-AID 1 is a multinational, phase 3, balanced-randomized, double-blind, placebo-controlled, parallel-group clinical study. Newly diagnosed patients (N = 457, aged 16-45 years) were randomized to subcutaneous injections of DiaPep277 or placebo quarterly for 2 years. The primary efficacy end point was the change from baseline in the area under the glucagon-stimulated C-peptide curve. Secondary end points were the change from baseline in mixed-meal stimulated C-peptide secretion and in fasting C-peptide and achieving target HbA 1c ≤7% (≤53 mmol/mol). Partial remission (target HbA 1c on insulin ≤0.5 units/kg/day) and hypoglycemic event rate were exploratory end points. RESULTS: DiaPep277 was safe and well tolerated. Significant preservation of C-peptide secretion was observed in the DiaPep277-treated group compared with the placebo (relative treatment effects of 23.4%, P = 0.037, and 29.2%, P = 0.011, in the modified intent-to-treat [mITT] and per-protocol [PP] populations, respectively). The mixed-meal stimulation failed to distinguish between the groups. There was a trend toward efficacy in fasting C-peptide levels, though not statistically significant. Significantly more DiaPep277-treated than placebo-treated patients maintained target HbA 1c (mITT 56% versus 44%, P = 0.03; PP 60% versus 45%, P = 0.0082) and entered partial remission (mITT 38% versus 29%, P = 0.08; PP 42% versus 30%, P = 0.035). DiaPep277 treatment reduced the relative hypoglycemic event risk (mITT by 20%; PP by 28%). CONCLUSIONS: DiaPep277 safely contributes to preservation of β-cell function and to improved glycemic control in patients with type 1 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=84899115551&partnerID=8YFLogxK
U2 - 10.2337/dc13-1391
DO - 10.2337/dc13-1391
M3 - Article
AN - SCOPUS:84899115551
SN - 0149-5992
VL - 37
SP - 1392
EP - 1400
JO - Diabetes Care
JF - Diabetes Care
IS - 5
ER -